Ultrasonography Noninferior to Radiography for Pediatric Distal Forearm Injury
05 Jun 2023
Clinical ResultClinical Study
MONDAY, June 5, 2023 -- For children presenting to the emergency department with an isolated distal forearm injury, initial point-of-care ultrasonography is noninferior to radiography for physical function of the affected arm at four weeks, according to a study published in the June 1 issue of the New England Journal of Medicine.
Peter J. Snelling, M.B.B.S., M.P.H., from the School of Medicine and Dentistry and Menzies Health Institute Queensland in Brisbane, Australia, and colleagues conducted a multicenter, noninferiority trial involving patients aged 5 to 15 years who presented to the emergency department with an isolated distal forearm injury without clinically visible deformity. Participants were randomly assigned to an initial point-of-care ultrasonography or radiography and were followed for eight weeks. Physical function of the affected arm at four weeks was assessed as the primary outcome with the validated Pediatric Upper Extremity Short Patient-Reported Outcomes Measurement Information System (PROMIS) score.
Outcomes were available for 262 of the 270 participants enrolled. The researchers found that PROMIS scores at four weeks were noninferior in the ultrasonography group versus the radiography group (mean, 36.4 and 36.3 points; mean difference, 0.1 point; 95 percent confidence interval, −1.3 to 1.4). In 266 participants with primary outcome data recorded at any time, intention-to-treat analyses produced similar results (mean difference, 0.1 point; 95 percent confidence interval, −1.3 to 1.4). No clinically important fractures were missed.
"Ultrasonography was noninferior to radiography in the outcome of physical function of the arm at four weeks, with no between-group differences in the occurrence of adverse events," the authors write.
Abstract/Full Text (subscription or payment may be required)
Posted June 2023
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.